Neuroactive steroids exhibit better neuroprotective properties in vitro and in vivo, and will be a potential neuroprotective effect. In this study, polyhydroxy sterone 2β, 3α, 5-trihydroxy-5α-androst-6-one (YC10) was designed and synthesized from androst-5-en-3-ol by 6 steps reactions. Its absolute structure was characterized by X-SCD and its structure was characterized by NMR, IR, and MS. Its neuroprotective action was determined by MTT assay with two models of neurotoxicity. The maximum protective effect was at a concentration of 40μM for neurotoxicity induced by glutamate, and showing better cell viability in a dose-dependent manner; Moreover it cloud significantly protect the cerebellar granule neurons against neuronal death mediated by low K + , its effective protective concentration was 50μM.
Introduction
Neurosteroids are synthesized within the brain and are endogenous regulators of seizure susceptibility, anxiety and stress [1] [2] , and such as allopregnanolone has neuroprotective properties in vitro and in vivo [3] . Some synthetic neuroactive steroids show better potential neuro protection and is a type of potential neuro protectant for the treatment of neurological disorders including epilepsy, traumatic brain injury and stroke [4] [5] [6] , In a previous study, we synthesized some polyhydroxy steroids such as 5α-cholest-3β,5,6β-triol and 5α-androst-3β,5,6β-triol ( Fig. 1 ) which exhibited significant neuroprotective effects in multiple primary cultures in vitro and cerebral ischemia in vivo [7] [8] [9] [10] [11] , and the some results showed that 5α-androst-3β,5,6β-triol without side chain showed better neuroprotection than 5α-cholest-3β,5,6β-triol. (Fig. 1 ) is a natural polyhydroxy sterone which is a kind of vertebrate hormone found in insects and few plants. It can regulate the molting, metamorphosis and reproduction of arthropods, and have a potent neuroprotective effect by inhibition of oxidative stress RESEARCH ARTICLE [12] [13] . The interesting research hinted us that new structure of polyhydroxy sterone without side chain maybe will have better effective neuroprotection. In present study, we designed and synthesized a new polyhydroxy sterone without side chain and evaluated its bioactivities on two models of neurotoxicity.
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Materials and Methods
Materials and Instruments: 3β-Hydroxy-androst-5 -en-17-one (dehydroepiandrosterone, DHEA) were used as starting materials were purchased from Wuhan Yuancheng Technology, China. All chemicals and solvents were of analytical grade and purchased from Guangzhou Chemical Reagents Company China if not mentioned particularly. All melting points were measured on an YRT-3 melting point apparatus and were uncorrected. All reactions were monitored by thin-layer chromatography (TLC) on silica gel GF254. The products were purified by column chromatography over silica gel (Qingdao Haiyang Chemical Co., 200-300 mesh). The IR spectra were recorded as KBr pellets on an EQUINOX 55 FT spectrophotometer (wave numbers in cm -1 ).
1 H NMR and 13 C NMR spectra were recorded on a nuclear magnetic resonance spectrometer Bruker (Avancell, 400 MHz) with TMS as internal standard in CDCl 3 or DMSO-d 6 . MS were recorded on a Agilent 6120 spectrometer by atmospheric pressure chemical ionization (APCI). Analytical HPLC was performed on an Agilent apparatus 1260. A prepacked C18 reverse-phase column ( Phenomenex Gemini: 250×4.6mm，5μm) was used for analytical HPLC with a binary gradient elution (H 2 O/MeOH： 30:70), column temperature was 40℃, and a flow rate of 1ml min -1 , the detector was RID.
3β-Hydroxy-androst-5-en-3-tosylate (2) To a solution of compounds 1 [9] (14.64g，0.053mol ) in anhydrous pyridine, p-toluenesulfonyl chloride (26.05g ， 0.137mol) was added. The solution was stirred at room temperature for 24 h. After completion as indicated by TLC, the mixture was slowly poured into cold water with 500mL 17% hydrochloric acid. The mixture was stirred until the solid became dispersed particles which were filtered under reduced pressure to give crude product of 2, which was subjected to the next step without any purification. To a solution of 2 (15.00 g， 0.035 mol) in 200 mL CH 2 Cl 2 , 200 mL water and Na 2 CO 3 (23.32 g，0.22mol) were added. The reaction mixture was stirred vigorously, and m-chloroperbenzoic acid (15.12g ， 0.088mol) was added slowly. The mixture was stirred for 5 h at 0℃, and then the aqueous layer was extracted with CH 2 Cl 2 . The combined CH 2 Cl 2 extracts were washed successively with 5% Na 2 SO 3 solution, saturated NaHCO 3 solution, and water, dried over anhydrous Na 2 SO 4 , and evaporated to dryness to give white crude epoxide that was purified on a silica gel column by eluting with petroleum/EtOAc (35:1) to obtain pure 3. White solid ( 12. 3β-Tosyloxy-5-hydroxy-5α-androst-6-one (4) A solution of epoxide 3 (14.07g, 31.64mmol) in 750 mL acetone was treated with Jones Reagent (30 mL) and stirred for 2 h at room temperature. After the reaction was finished by monitored of TLC, the reaction was ended with isopropanol. Neutralizing with Na 2 CO 3 solution, the mixture was evaporated to a fifth of the initial volume, diluted with water, and extracted with ethyl acetate (3 times). The combined organic extracts were washed with water, dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness. Purification on a silica gel column by eluting with petroleum/EtOAc (10:1) to obtain pure 4. White solid (12 5-hydroxy-5α-androst-2-en-6-one (5) Lithium bromide (18.01g, 0.207mol) and lithium carbonate (15.33g, 0.207mol) were added to a solution of 4 (11.94g， 0.026mol) in 150 mL dry DMF, and the mixture was refluxed for 3 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution and stirred sharply. Then dark brown precipitation occured and be filtered. The product was washed with water to neutral and then dry it in a vaccum oven to give a brown solid that was purified on a silica gel column by eluting with petroleum/EtOAc (18:1) to obtain pure 5. 2,3-Epoxy-5-hydroxy-5α-androst-6-one (6) To a solution of 5 (4.6g, 0.016mol) in 120 mL CH 2 Cl 2 , 120 mL water and Na 2 CO 3 (10.6 g, 0.10 mol) were added. The reaction mixture was stirred vigorously, and m-chloroperbenzoic acid (6.92g, 0.04mol) was added slowly. The mixture was stirred for 5 h at 0℃, and then the aqueous layer was extracted with CH 2 Cl 2 . The combined CH 2 Cl 2 extracts were washed successively with 5% Na 2 SO 3 solution, saturated NaHCO 3 solution, and water, dried over anhydrous Na 2 SO 4 , and evaporated to dryness to give white crude epoxide that was purified on a silica gel column by eluting with petroleum/EtOAc (10:1) to obtain pure 6. 2β,3α,5-trihydroxy-5α-androst-6-one (YC-10)
A solution of epoxide 6 (2.89g, 0.009mol) in 150 mL acetone was treated with 20 mL 1 N H 2 SO 4 solution and stirred for 3 h at room temperature. After neutralization with Na 2 CO 3 solution, the mixture was evaporated to a fifth of the initial volume, diluted with water, and extracted with ethyl acetate. The combined organic extracts were washed with water, dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness. Purification on a silica gel column by eluting with petroleum/ EtOAc (1:1) to obtain pure YC-10. White solid, (1.5 g, 51.7%), m.p.213. 4 GlutaMAX, Trypsin solution, Penicillin-Streptomycin (P/S) was purchased from Gibco®, Life Technologies. Other chemicals, if not mentioned particularly, were all purchased from Sigma-Aldrich. Cerebellar granule neurons (CGNs) were prepared from Sprague Dawley rat pups 7-8 days postpartum as described previously with little modification [18] . Briefly, neurons were dissociated from freshly dissected cerebella by mechanical disruption in the presence of trypsin and DNase and were then plated on poly-L-lysine-coated Nunc culture plates (Fisher, Pittsburgh, Pa.). Cells were seeded at a density of 2.0×10 6 /ml in basal modified Eagle medium (BME) containing 10% fetal bovine serum, 25mM KCl, 2mM glutamine, and penicillin (10 U/ml)-streptomycin (10 μg/ml). Cytosine arabinoside (10 μM) was added to the culture medium 24 h after plating to limit the growth of nonneuronal cells. With this protocol, 95 to 99% of the cultured cells were granule neurons.
Glutamate-induced neurotoxicity in cerebellar granule neurons At 8 day in vitro, cultures were pretreated with compounds half an hour before glutamate exposure. Afterwards, model group and all dose groups were exposured to Locke Buffer without Mg 2+ and treated with final concentrations of 100 μM glutamate, 10 μM glycine and corresponding drugs. Cultures were placed in an incubator at 37℃ for 30 minutes and then neurons were passed on to normal cultures to be cultured for 24 h [14] . Low-K + -mediated neuronal death in cerebellar granule neurons At 8 day in vitro, cultures were pretreated compounds 30 minutes before low K + exposure. Afterwards, model group and all dose groups were changed the cultures with the concentration of KCl from 25 mM (25 K) to 5 mM (5 K) and treated with corresponding drugs. Cultures were placed in an incubator at 37℃ for 24 hours [15] .
Neuronal viability
Neuronal viability was measured by MTT assay. MTT reduction was measured in each group after drug treatment and data was presented as percentage of normal control group. FDA were used as indicator of living cells. Images were acquired from a fluorescent microscope.
Statistical analysis
Results are expressed as means±S.E. Data were analyzed by ANOVA, followed by Dunnett's test, with P < 0.05 being considered to indicate significance.
Results
Synthetic route of YC-10
The common feature of the aimed compound contains 2β,3α,5α-trihydroxy and 6-one groups, and how to obtain them is the key steps for the synthetic work. First the 3-hydroxy group should be protected by TsCl from oxidation and the protected group could be eliminated to form double bond in the later elimination reaction; then 6-one group was obtained by oxidization of Jones reagent from 5,6-epoxy compound; moreover the 2β,3α-dihydroxy group were prepared by oxidization of mCPBA and acid hydrolysis. The synthetic route is showed in scheme 1.
Configuration
We obtained the single crystal structure of YC-10 ( Fig.2) , and deposition numbers of its CIF file is CCDC 1498662. , F (000) = 1428, R = 0.0350, wR = 0.0876, S = 1.041. The crystal datum showed that R = 0.0350, so its structure is absolute configuration which 2-OH and 5-OH is at the same side with 19-CH 3 , and the 3-OH is at the another side with 19-CH 3 , So the aimed compound was named 2β,3α,5-trihydroxy-5α-androst-6-one. The feature of 13 C NMR of compounds YC-10 contained three peaks at 68.89, 70.17, 79.66 ppm and one peak at 210.57 ppm which showed that the compound have 2β,3α,5-trihydroxy groups and 6-one group.
The neuroprotection against neuronal damage induced by glutamate Typical photomicrogra-phs illustrating the effect of YC-10 on glutamate-induced neurotoxicity are shown in Fig.  3 . In contrast to control neurons, glutamate-exposured cells resulted in cell death in cerebellar granule neurons. Live staining by FDA showed a decrease in intact living cells (green) in model of neuronal damage induced by glutamate. Pretreatment with YC-10 improved neuronal survival (increased FDA stained cell number) with the maximum effect at a concentration of 40 μM. Neurons pretreated with YC-10 were showing better cell viability in a dose-dependent manner with the maximum effect reaching over 100% of normal control as well as the positive control MK801 (Fig.  3b) . 
Discussion
In present study, the aimed compound YC-10 was designed and synthesized, and its absolute structure and common structure were characterized by single structure and spectra datum. YC-10 showed neuroprotective action with the maximum effect at a concentration of 40 μM which is equal to that of MK801. In addition, it was dose-dependent neuroprotection against neuronal damage. Likewise, it can protect neurons from cell death mediated by low potassium. Aimed compound YC-10 showed a promising neuroprotective effect to be a candidate for further neuroprotectant investigation. We herein for the first time report the synthetic route and bioactivity of YC-10 in well established neurotoxicity or neuronal death models.
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